ZG005 for Injection

BIOLOGICAL6 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions

Advanced Solid TumorHepatocellular CarcinomaLymphomaNon-small Cell Lung Cancer

Phase 1

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

RecruitingNCT06883526

Suzhou Zelgen Biopharmaceuticals Co.,LtdLymphoma

Start: 2025-05-16End: 2027-05-31Target: 60Updated: 2026-01-05

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

RecruitingNCT06903377

Suzhou Zelgen Biopharmaceuticals Co.,LtdNon-small Cell Lung Cancer

Start: 2025-05-23End: 2027-05-31Target: 50Updated: 2026-01-05

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

RecruitingNCT06938880

Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Solid Tumor

Start: 2025-05-20End: 2028-04-30Target: 60Updated: 2026-01-05

Phase 2

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

RecruitingNCT06558227

Suzhou Zelgen Biopharmaceuticals Co.,LtdHepatocellular Carcinoma

Start: 2024-10-24End: 2026-10-31Target: 90Updated: 2024-12-16

Study of ZG005 in Patients With Advanced Solid Tumors

Active, not recruitingNCT06927687

Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Solid Tumor

Start: 2025-06-13End: 2027-06-01Updated: 2026-04-29

Phase 3

ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular

Not yet recruitingNCT07813572

Suzhou Zelgen Biopharmaceuticals Co.,LtdHepatocellular Carcinoma

Start: 2026-09-01End: 2032-09-01Target: 600Updated: 2026-09-10

Related Papers

Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial.

Journal of Clinical Oncology2026-05-27